Table of Contents
PPT Slide
PPT Slide
Investment Thesis
U.S. HIV Landscape
Fusion Inhibitors
TORO (T-20 vs. Optimized Regimen Only
TORO-1
TORO-1
TORO-1
TORO Clinical Trials
TORO-1 Subgroup Analysis
Baseline PSS score: Subgroup analysis of mean change from baseline in log10 HIV-1 RNA at week 24 (ITT population)
Fusion Inhibitors May Become the Therapeutic Foundation for Treatment Experienced Patients
PPT Slide
Estimated Time and Event Schedule for Fuzeon Filing and Launch
Current U.S. HIV Market – $3.3Bn
New Classes/Drugs Expand Antiretroviral Market
U.S. HIV Patient Segments
Fuzeon Launch
Fuzeon Growth Strategies
Second Generation Fusion Inhibitor T-1249
T1249-101
Fusion Inhibitor Franchise Expansion
Senior Management Team
Financial Position
Upcoming Fusion Inhibitor Presentations
Milestones
PPT Slide
|